Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31478419 | 0.85 | TSHR (0.48) | CES2CES1MEN1KMT2AKDM4E | |
| SCHEMBL2459005 | 0.83 | MEN1 (0.59) | CES2CES1MEN1KMT2AKDM4E | |
| SCHEMBL19367869 | 0.83 | CES1 (0.59) | CES2CES1MEN1KMT2AKDM4E | |
| SCHEMBL29162697 | 0.82 | CES2 (0.48) | CES2CES1MEN1KMT2AKDM4E | |
| SCHEMBL2056918 | 0.82 | MEN1 (0.56) | CES2CES1MEN1KMT2AKDM4E | |
| SCHEMBL15173675 | 0.80 | HCAR2 (0.53) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL452462 | 0.80 | PLOD2 (0.56) | CES2CES1MEN1KMT2AKDM4E | |
| SCHEMBL2908590 | 0.78 | PLOD2 (0.55) | CES2CES1MEN1KMT2AKDM4E | |
| SCHEMBL13886370 | 0.78 | MEN1 (0.49) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL7220761 | 0.77 | CES1 (0.52) | CES2CES1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271925-A1 | NOVEL TNF ACTIVITY INHIBITOR COMPOUND, AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ILAb Co., Ltd. (KR) | 2023-08-31 | — | — | US | disclosed |
| EP-4180423-A1 | NOVEL TNF ACTIVITY INHIBITOR COMPOUND, AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ILAb Co., Ltd. (KR) | 2023-05-17 | — | — | EP | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| EP-1915053-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007022073-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271925-A1 | NOVEL TNF ACTIVITY INHIBITOR COMPOUND, AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TNF, NFKBIA, TNFRSF9 | CES2 3504/4885CES1 888/4885MEN1 3757/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | CES2 299/4885CES1 191/4885MEN1 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.